Further patient advocacy is needed to ensure that recipients of HCV-infected organs have access to direct-acting antivirals as early as possible, including in a prophylactic manner, if data continue to support its benefit.
The opioid epidemic has fueled the transmission of HCV, particularly among younger persons, who are often unaware of their risks and prevented from receiving timely treatment due to a variety of care barriers, even in settings ideally suited to identifying and treating HCV.
A study published in the Annals of Internal Medicine found transplanting kidneys from hepatitis C virus (HCV)-positive donors to HCV-negative recipients (HCV D+/R-) may be successful with prophylactic treatment with direct-acting antivirals.
Researchers assessed changes among an aging population of people with chronic hepatitis C virus who are treated with DAAs, including the development of comorbidities and changes in liver disease severity.
Researchers found that no patients with concomitant COVID-19 and hepatitis B virus infection progressed to severe or critically ill status during hospitalization, but many had abnormal liver function tests on admission.
Numerous reports have indicated gastrointestinal, cardiovascular, and neurologic manifestations, in addition to the noted respiratory effects, in patients with COVID-19, and up to 50% of patients with COVID-19 may experience hepatic manifestations.
In parallel to the ongoing national opioid crisis, the incidence rate of infective endocarditis cases has increased markedly among people aged 18 to 29 years with hepatitis C virus infection and those with opioid use disorder.
Patients with chronic hepatitis C (HCV) achieving sustained virologic response to pegylated interferon plus ribavirin therapy did not exhibit an effect on the incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis.